National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.

 

Rapid Review

Commenced Completed Outcome
26/09/2016 23/11/2016 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations.

7/03/2018 – The European Medicines Agency (EMA) has recommended the immediate suspension and recall of daclizumab.